The American Association for Cancer Research (AACR) has awarded twenty undergraduate students with the AACR-Thomas J. Bardos Science Education Awards. The award recipients will receive financial support to attend two consecutive Annual Meetings and participate in educational programs, such as a special high school student program.
The American Association for Cancer Research (AACR) has awarded scholarships to 91 minority and underrepresented scientists participating in its Annual Meeting. The AACR offers several award programs, including the Minority Scholar Awards, which support early-career scientists from traditionally underrepresented groups.
Tony Hunter and Raymond N. DuBois have been awarded prestigious Landon-AACR Prizes for their significant contributions to understanding, treatment, and prevention of cancer. Their work has led to the development of anti-cancer drugs and potential mechanisms to inhibit enzyme activity.
Dr. Korsmeyer's work on BCL-2 identified its role in blocking cell death and established a mammalian apoptotic pathway. His research has significantly impacted cancer treatment and our understanding of biology and medicine.
The American Association for Cancer Research has honored scientists who have made significant contributions to the prevention, detection, and treatment of cancer. These awards recognize outstanding achievements in basic research, clinical care, therapeutics, and prevention.
Scientists have developed new therapies targeting survivin and VEGF to induce cancer cell death. LY2181308 inhibits survivin expression, while a novel VEGF receptor, R2Fas, triggers apoptosis in blood vessels and cancer cells. These approaches show promise for treating various types of cancers.
Researchers found tumor shrinkage and arrest in patients with advanced malignancies treated with SU11248, an oral histone deacetylase inhibitor SAHA, and BAY 43-9006, targeting angiogenesis and cell growth signaling molecules. These preliminary results confirm the promise of these therapeutic approaches.
Researchers at Baylor College of Medicine have identified a novel secretory protein specific to neuroblastoma, which could provide clues to differentiating between aggressive tumors and those that are more likely to respond to treatment. Additionally, scientists have discovered selective inhibitors of key protein kinases implicated in ...
A clinical study found that molecular markers can predict which head and neck cancer patients will respond better to radiotherapy. The study identified two tumor profiles with different clinical outcomes, one with a high response rate of 67% and another with a poor response rate of 37%.
Researchers found that PABA significantly improves the effects of chemotherapy drugs and radiation on cancer cells. Additionally, FES PET imaging can predict response to endocrine therapy in breast cancer patients by measuring regional target expression.
Recent research suggests that at least eight central 'clock' genes coordinate cell proliferation and apoptosis in circadian time. Studies have shown that tumor growth is organized within a daily cycle, with tumors growing twice as fast during the active phase. This discovery may lead to new therapeutic targets for cancer treatment.
Researchers will discuss novel targets for controlling cancer growth, such as the circadian rhythm of cells and VEGF, a key player in tumor angiogenesis. The conference also aims to improve radiotherapy effectiveness for head and neck cancers by tailoring therapy to individual tumors.
Researchers have found that pomegranate fruit extract and grape polyphenol resveratrol exhibit anti-skin tumor effects by inhibiting cancer-promoting pathways. These findings suggest potential benefits for skin cancer prevention and treatment.
Researchers found that ginger compounds slowed tumor development in mice, while Scutellaria barbata inhibited apoptosis in prostate cancer cells. These findings suggest potential chemopreventive effects of these natural herbs against certain cancers.
Research suggests green tea consumption may prevent cancer and reduce oxidative DNA damage, with potential chemopreventive effects of green tea polyphenols. The study also identified novel EGCG analogs with potent anti-tumor activity.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Research studies reveal that weight loss, exercise, and dietary changes can lower breast cancer risk by up to five percent of body weight and increase physical activity levels associated with reduced mammographic breast density. Additionally, a low-carbohydrate diet may be more effective in preventing prostate cancer progression.
Dr. Hong's work has accelerated the pace of growth in cancer prevention research, opening doors to less toxic and more effective chemopreventive agents and regimens. His research has demonstrated the effectiveness of biochemoprevention in reducing both primary and recurrent cancers.
The American Association for Cancer Research (AACR) accepts applications for several research fellowships to support salary and benefits for postdoctoral and clinical fellows. The deadline is Wednesday, October 15, 2003, and awards are open to researchers worldwide.
The AACR-Gertrude B. Elion Cancer Research Award supports meritorious basic, translational, or clinical cancer research by a tenure-track scientist at an academic institution worldwide. Five Career Development Awards will be granted in 2004 to support research in various areas of cancer research.
The American Association for Cancer Research (AACR) is seeking nominations for its Professorship in Basic Cancer Research, which provides a $50,000 grant for research expenses. The AACR-NFCR Professorship was established to honor Franklin and Tamara Salisbury and support cutting-edge basic cancer research.
The American Association for Cancer Research (AACR) is accepting nominations for several prestigious awards and lectureships, recognizing outstanding contributions in epidemiology, clinical cancer research, and preclinical research. The deadline for submissions is September 12, 2003.
Researchers have developed molecular markers that can predict radiation-induced late toxicity and disease recurrence in prostate cancer. The study used apoptosis assays to evaluate cell death induced by radiation, revealing correlations between lymphocyte apoptosis and toxicities.
Researchers have developed novel compounds that significantly improve anti-cancer therapy outcomes. The AvastinTM clinical trial shows that bevacizumab, an anti-angiogenesis agent, can slow or stop tumor growth and increase patient survival when combined with chemotherapy.
A recent study found that women with higher plasma cysteine levels had a significantly reduced risk of developing breast cancer. The association was strongest among leaner women, suggesting potential chemopreventive benefits against breast cancer.
Researchers identified 58 genes dissimilar between normal and left-sided tumor samples, and 118 between normal and right-sided tumor samples. The study provides new insights into why some patients respond to treatment while others do not.
Researchers have discovered a new bone-targeted mTOR inhibitor that decreases both tumor proliferation and bone breakdown for the treatment of bone cancer. Additionally, studies have shown efficacy of radioimmunotherapy using radiolabeled HerceptinTM in combination with gemcitabine in treating intraperitoneal disease.
A new study suggests that telomere dysfunction may play a causal role in human intraepithelial neoplasia (IEN) found in precancers. Short telomeres were found in the majority of precursor lesions across various types of cancers, indicating potential early molecular mechanisms underlying cancer development.
A new test using ProPSA detected prostate cancer at lower PSA levels, identifying more aggressive forms of the disease. The test improved detection of early aggressive cancer in men who may not have been caught until it was too late.
Researchers used blood samples to analyze protein patterns and determine if biopsies were necessary. The test showed a sensitivity of 100% and specificity of 67%, suggesting it could save over 50% of biopsies. The study's results may lead to more accurate cancer detection and tailored therapy for individual patients.
Two studies suggest that regular use of ibuprofen and aspirin inhibits breast cancer formation, while a low-dose tamoxifen regimen may effectively treat breast cancer with fewer side effects. Another study found that a combination of low-dose COX-2 inhibitors and fish oil may reduce colon cancer risk.
The AACR is now accepting nominations for its Cancer Prevention Research Award. Candidates must have made significant contributions to the field and be able to present a lecture at an upcoming conference in Phoenix, Arizona. The winner will receive $5,000 and support to attend the meeting.
The Avon Foundation-AACR International Scholars in Breast Cancer Research program provides two-year grants to four junior-level faculty members from limited opportunities countries. The program aims to enhance breast cancer research and clinical care globally.
A study demonstrated that low-dose tamoxifen can maintain clinical effect against breast cancer, reducing Ki-67 levels and tumor proliferation. The study found no dose response, suggesting that lower doses of the drug may be equally effective in treating ER-positive breast cancer.
Women taking two or more NSAIDs per week for five to nine years reduced their breast cancer risk by 21-28%. Ibuprofen was found to be more effective than aspirin in preventing breast cancer. The study's findings suggest that COX-2 inhibition may play a role in limiting breast tumor growth.
A novel combination treatment of celecoxib, a COX-2 inhibitor, and DHA from fish oil causes cell death in human colon cancer cells at low doses. This synergistic approach shows promise in reducing colon cancer risk with tolerable doses.
Regular NSAID use for five to nine years reduces breast cancer risk by 21%, while ten-year use increases the reduction to 28%. The study enrolled 80,741 post-menopausal women with no reported history of cancer, other than non-melanoma skin cancer.
The study identified a new gene associated with breast cancer, C35, which is over-expressed in 65% of breast cancers. Researchers believe that traditional treatment methods alone will not be effective against C35 positive breast cancer and are exploring a two-pronged approach for treatment.
A new generation of medical treatment is being driven by proteomics, enabling early detection of cancer and personalized therapy. The technology uses multiple high-resolution serum proteomic patterns to detect disease, with 85% accuracy in diagnosis.
AACR sponsors science programs for high school and undergraduate students to inspire careers in cancer research. The AACR-Thomas J. Bardos Science Education Awards for Undergraduate Students recognize and nurture talented young scientists.
The American Association for Cancer Research (AACR) has awarded several prestigious grants to outstanding cancer researchers. The AACR-National Foundation for Cancer Research Professorship in Basic Cancer Research supports Dr. Manuel Perucho's research on gastrointestinal cancer mechanisms. Additionally, the AACR-Gertrude B. Elion Canc...
The American Association for Cancer Research (AACR) has established programs to support minority and underrepresented scientists in cancer research, including the AACR-Minority Scholar Awards in Cancer Research. The programs aim to increase career advancement opportunities for these researchers.
Charles J. Sherr and Dennis J. Slamon are being honored with the Landon-AACR Prizes for Cancer Research, recognizing their significant contributions to understanding mechanisms of cell growth control and developing targeted cancer therapies.
This year's AACR honorees have made significant advances in understanding and treating cancer. The winners include Mario R. Capecchi, Ronald A. DePinho, Carlos L. Arteaga, Malcom F. Stevens, Martin J. Blaser, David S. Alberts, Graham A. Colditz, Janet D. Rowley, who will receive awards for their outstanding research in various areas of...
A recent study by the American Association for Cancer Research found that patients with advanced melanoma expressing higher levels of melanoma-associated antigens (MAAs) experienced significantly improved survival outcomes. The study suggests that these tumors may be more responsive to immunotherapy, such as vaccines against melanoma.
A new study found that genetic test results for HNPCC may motivate colonoscopy screening among those who test positive, increasing screening rates. The American Association for Cancer Research recommends more targeted training on screening recommendations for underserved communities.
Researchers used precancerous breast cells from patients with Li-Fraumeni syndrome to test the effectiveness of chemopreventive agents in preventing cancer. Treatment with tamoxifen, a p53-rescue drug, and PPAR-ã agonist showed promise in stopping cancer development, suggesting new potential therapies for high-risk individuals.
Researchers discovered that telomere shortening is a common feature in high-grade prostatic intraepithelial neoplasia (HGPIN), the precursor to prostate cancer. Shortened telomeres were found in 93% of HGPIN lesions, suggesting their role as potential biomarkers for early detection and prevention.
Researchers have found that topical retinoids, such as tazarotene, may be a safer alternative for preventing skin cancer in individuals at risk. The study used mice with basal cell nevus syndrome, a genetic disorder that predisposes them to developing large numbers of basal cell carcinomas.
The American Association for Cancer Research (AACR) is calling on the FDA to accelerate the development and approval of chemopreventive agents for precancerous cells. Emerging technologies have improved detection capabilities, but drug approvals remain limited due to concerns about treatment efficacy in high-risk populations.